RARA and thyroid cancer: Subsequently, through cell experiments, molecular experiments, and in vivo experiments, it was unveiled that LBX2-AS1 boosts the transcriptional activity of FSTL3 by recruiting the binding of RARα, thereby hastening progression of thyroid cancer cells.